Track market-moving stories before they get noisy

 | Source: Geron Corporation

Presentations feature real-world experience and clinical evidence in lower-risk MDS, underscoring growing global scientific engagement with imetelstat 

FOSTER CITY, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, today announced two oral presentations and one poster presentation highlighting imetelstat in patients with lower-risk myelodysplastic syndromes (LR-MDS) at the 88th Annual Meeting of the Japanese Society of Hematology and the 2026 Annual Meeting of the German, Austrian and Swiss Societies for Hematology and Medical Oncology. These presentations will feature real-world evidence and findings from the Phase 3 IMerge trial.

“We’re encouraged by the growing interest in imetelstat across the global hematology community, supported by both the clinical evidence from IMerge and an expanding body of real-world evidence in lower-risk MDS,” said Joseph E. Eid, M.D., Executive Vice President, Research and Development and Chief Medical Officer of Geron. “These presentations provide an important opportunity to share evidence relevant to patient populations across regions and engage with clinicians as we evaluate opportunities to bring imetelstat’s potential to more people living with LR-MDS around the world.”

Key takeaways from the presentations:

88th Annual Meeting of the Japanese Society of Hematology 2026

Real-World Experience With Imetelstat in Lower-Risk Myelodysplastic Syndromes: Insights From United States Claims Data (Eid, et al. Oral #O1-11C-4) The retrospective study used closed medical and pharmacy claims with linked enrollment and laboratory data from the Komodo Health database and included adults with MDS who initiated imetelstat between June 2024 and August 2025, representing the first 14 months after the launch of imetelstat in the U.S.In this real-world U.S. cohort (N=58), with a mean age of 75 years at diagnosis, most patients (71%) initiated imetelstat in the third line or later, with considerable anemia and a mean Charleson Comorbidity Index of 2.6 at the time of initiation.Despite substantial comorbidity burden, most patients remained on therapy through the early months when cytopenias typically emerge (~67% at 6 months; Kaplan-Meier [KM] estimate). Durable Clinical Outcomes With Imetelstat in Korean Patients With LR-MDS (Eid, et al. Poster #P3-12-5) This post-hoc study explores characteristics of two Korean patients with LR-MDS who had over one year of red blood cell transfusion independence (RBC-TI) with imetelstat, and explores the relationship between cytopenias and treatment outcomes with imetelstat in 13 Korean patients from the Phase 2/3 and heart rate-corrected QT interval (QTc) substudy of IMerge.Both patients who achieved long-term response with imetelstat experienced grade 3/4 neutropenia and grade 3/4 thrombocytopenia events early during treatment; most resolved to grade ≤2 in <4 weeks, consistent with the broader IMerge data.Durable efficacy and manageable safety with imetelstat was exhibited in Korean patients across a range of patient and disease characteristics (sex, RS status, baseline erythropoietin [EPO], and baseline platelet levels).In the 13 Korean patients, early cytopenias with imetelstat were associated with better clinical outcomes, as previously reported in IMerge. 2026 Annual Meeting of the German, Austrian and Swiss Societies for Hematology and Medical Oncology

Telomerase Inhibition With Imetelstat in Patients With Lower-Risk Myelodysplastic Syndromes: Integrating Molecular Findings, Cytopenias, and Clinical Outcomes (Brauer, et al. Oral #V755) This presentation integrates key evidence from the Phase 2/3 and QTc substudy of IMerge to support clinical practice, reporting on molecular changes, cytopenias and clinical outcomes with imetelstat in LR-MDS, including emerging evidence suggesting treatment may potentially alter the underlying biology of the disease.Transient cytopenias observed early in treatment may be the result of an on-target effect of imetelstat and may be predictive of a better therapeutic response.Certain patients with LR-MDS and transfusion-dependent (TD) anemia who experience sustained RBC-TI (≥8-week, ≥24-week, or ≥1-year) with imetelstat may experience improved health-related outcomes, including fatigue, QUALMS Total, QUALMS-P, and QUALMS-E scores. The presentations are available on the “Publications & Presentations” page of the Geron website.

About RYTELO (imetelstat)
RYTELO (imetelstat) is an oligonucleotide telomerase inhibitor approved in the U.S. for the treatment of adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). It is indicated to be administered as an intravenous infusion over two hours every four weeks.

In addition, RYTELO is approved in the European Union as a monotherapy for the treatment of adult patients with transfusion-dependent anemia due to very low, low or intermediate risk myelodysplastic syndromes without an isolated deletion 5q cytogenetic (non-del 5q) abnormality and who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy.

RYTELO is a first-in-class treatment that works by inhibiting telomerase enzymatic activity. Telomeres are protective caps at the end of chromosomes that naturally shorten each time a cell divides. In LR-MDS, abnormal bone marrow cells often express the enzyme telomerase, which rebuilds those telomeres, allowing for uncontrolled cell division. Developed and exclusively owned by Geron, RYTELO is the first and only telomerase inhibitor approved by the U.S. Food and Drug Administration and the European Commission.

Please see RYTELO (imetelstat) full Prescribing Information, including Medication Guide, available at https://pi.geron.com/products/US/pi/rytelo_pi.pdf.

About Geron
Geron is a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer. Because patients cannot wait, we approach our work with urgency, bringing together deep expertise in telomerase biology with patient perspectives and insights from clinical research and real-world care. Our medicine, RYTELO® (imetelstat), is approved in the United States and European Union for certain patients with lower-risk myelodysplastic syndromes (LR-MDS). We are building on our foundation in telomerase inhibition by studying imetelstat in myelofibrosis, including a pivotal Phase 3 clinical trial in patients with JAK-inhibitor relapsed/refractory disease, as well as other hematologic malignancies. Geron is a commercial-stage company with offices in Parsippany, New Jersey and Foster City, California. To learn more, visit www.geron.com or follow us on LinkedIn.

Use of Forward-Looking Statements

Except for the historical information contained herein, this press release contains forward-looking statements made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, those regarding: (i) the potential clinical significance of data presented from the IMerge trial and real-world evidence analyses; (ii) the potential relationship between treatment-emergent cytopenias and clinical outcomes; (iii) the potential for imetelstat to affect the underlying biology of lower-risk MDS; (iv) Geron’s plans and efforts to expand awareness and understanding of imetelstat through scientific engagement; (v) Geron’s plans to pursue opportunities to bring imetelstat to patients outside the United States; (vi) the future development of imetelstat in lower-risk myelodysplastic syndromes, myelofibrosis and other hematologic malignancies; and (vii) other statements that are not historical facts. These forward-looking statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. These risks and uncertainties, include, without limitation, risks and uncertainties related to: (a) whether data analyses and observations from clinical trials and real-world experience are predictive of future clinical outcomes; (b) whether imetelstat demonstrates disease-modifying activity or other benefits in patients; (c) whether treatment-emergent cytopenias are predictive of clinical outcomes or reflect on-target biological activity; (d) whether future clinical trial results, analyses and observations are consistent with prior findings; (e) whether regulatory authorities permit the continued development of imetelstat on a timely basis, or at all; (f) whether Geron is successful in commercializing RYTELO outside of the United States; (g) whether there are failures or delays in manufacturing or supplying sufficient quantities of RYTELO or clinical trial materials; and (h) risks and uncertainties relating to the development, regulatory review, and commercialization and market acceptance of imetelstat. Additional information regarding these risks and uncertainties and additional risks, uncertainties and factors that could cause actual results to differ materially from those in the forward-looking statements are contained in Geron’s filings and periodic reports filed with the Securities and Exchange Commission under the heading “Risk Factors” and elsewhere in such filings and reports, including Geron’s annual report on Form 10-K for the year ended December 31, 2025, and subsequent filings and reports by Geron. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made, and the facts and assumptions underlying the forward-looking statements may change. Except as required by law, Geron disclaims any obligation to update these forward-looking statements to reflect future information, events, or circumstances.

Investors and Media
Dawn Schottlandt
Senior Vice President, Investor Relations and Corporate Affairs
[email protected]

Geron Corporation: FDA Approval Fuels Stock Price SurgeGeron NASDAQ: GERN said it expects full-year net revenue from RYTELO to land in the mid-to-high end of its previously stated range, or approximately $230 million to $240 million, as the company continues to expand use of the telomerase inhibitor in lower-risk myelodysplastic syndromes, or MDS.

During the Cantor Healthcare Conference, Chief Executive Officer Harout Semerjian said Geron generated $57.5 million in net revenue during the second quarter, nearly $5 million above the preceding quarter. He said the company has now recorded three consecutive quarters of growth and reported that RYTELO revenue rose 24% in the first half of the year while operating expenses declined 4%.

Get Geron alerts:

Geron Stock Doubles After Imetelstat Receives FDA Panel Approval “We definitely see a path to profitability,” Semerjian said, noting that Geron’s revenue outlook and operating-expense guidance are both in the $230 million to $240 million range. However, he said the company is also focused on building a broader business and maintaining financial flexibility for future opportunities.

Community Expansion and Earlier-Line Use Semerjian said Geron’s commercial strategy has progressed from early engagement with academic medical centers toward greater penetration of community treatment settings. He said roughly 80% of lower-risk MDS patients are seen and treated in the community, particularly those in the second-line population targeted by RYTELO.

Geron is focusing on high-volume community accounts and on increasing use within accounts that have already adopted the treatment. Semerjian characterized this as a shift toward “depth” of use while the company continues to add new accounts.

The company is also seeking to move utilization toward earlier treatment lines. Semerjian said more than one-third of patients receiving RYTELO are now coming from earlier lines of therapy. He said Geron’s label and recently updated NCCN guidelines support use in the second-line setting, where the company believes its data are strongest and treatment duration may be longer than in later-line use.

While physicians may continue to use the therapy organically in later-line patients, Semerjian said Geron’s commercial efforts will center on second-line treatment.

European Strategy Under Review Geron has global rights to RYTELO and has received European Medicines Agency approval. Semerjian said the company plans to update investors by the end of the year on its strategy for markets outside the United States, including Europe.

Potential approaches could include partnerships, targeted commercial activity or use of contract sales organizations, he said. Geron does not plan to pursue a traditional model of building large country-by-country commercial teams in Europe.

Semerjian said the company is weighing pricing and policy considerations, including the evolving most-favored-nation, or MFN, discussion. He said management intends to preserve its flexibility and avoid making decisions that could undermine the company financially while pursuing broader patient access.

“RYTELO needs to be everywhere in the world, helping patients around the world,” Semerjian said. “We don’t necessarily need to be everywhere in the world.”

Myelofibrosis Study Discussions Continue Chief Medical Officer Joe Eid provided an update on Geron’s relapsed/refractory myelofibrosis study in patients who have failed JAK inhibitors. The trial, which completed enrollment in September of last year, uses overall survival as its primary endpoint.

Eid said Geron has been discussing the interim analysis with U.S. and European regulators to ensure the study’s framework reflects current regulatory expectations. The company is evaluating whether an interim result could potentially support a supplemental new drug application, though its previously communicated base case remains a final analysis in the second half of 2028.

The study could continue unchanged, reach a futility outcome or produce a positive result, Eid said. He added that Geron intends to complete regulatory discussions before any unblinding trigger is reached in order to preserve trial integrity.

The study permits certain control-arm patients to cross over to active treatment after a washout period and company review. Eid said the trial was designed with a buffer intended to prevent crossover from diluting the study’s statistical power.

Business Development and Capital Position Semerjian said Geron had more than $320 million in cash and has not exercised the final two tranches of a $125 million Pharmakon debt facility. The company recently added a chief business officer and is building capabilities to evaluate potential partnerships and business-development opportunities.

While RYTELO growth remains Geron’s top priority, Semerjian said the company may consider assets that fit its existing commercial and medical infrastructure. He said Geron does not need multibillion-dollar peak-sales assets to support its strategy and believes its available capital provides flexibility if attractive opportunities emerge.

About Geron (NASDAQ:GERN)Geron Corporation is a biopharmaceutical company focused on developing and commercializing treatments for myeloid hematologic malignancies, including certain bone marrow cancers. The company's approach centers on imetelstat, a telomerase inhibitor designed to target malignant stem and progenitor cells.

Geron's lead product, Rytelo (imetelstat), is approved in the United States for adults with lower-risk myelodysplastic syndromes who have transfusion-dependent anemia requiring or having failed treatment with erythropoiesis-stimulating agents.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in Geron Right Now?Before you consider Geron, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Geron wasn't on the list.

While Geron currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.